A comprehensive characterization of blood group antigen variants in the Middle Eastern population genomes - Insights into genetic epidemiology

Mercy Rophina^{1,2}, Kavita Pandhare^{1,2}, Vinod Scaria^{1,2}\$

¹CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB), Mathura Road, Delhi 110025, INDIA ²Academy of Scientific and Innovative Research (AcSIR), CSIR-HRDC Campus, Sector 19, Kamla Nehru Nagar, Ghaziabad, Uttar Pradesh 201002, INDIA

³Present address: Vishwanath Cancer Care Foundation (VCCF), Neelkanth Business Park, West Mumbai, 400086 India

Corresponding author Email:

Dr. Vinod Scaria - vinods@igib.in (Scaria V); Tel: 91-11-29879 109

Key points

- Large scale Middle Eastern population sequencing datasets including *The Greater Middle Eastern Variome, Genomes and exomes from Qatar and the Iranome* datasets were used in the study.
- A total of 2828 exomes and 88 genomes were analyzed accounting for a total of 18717 unique human blood group related variants.
- 2443 exonic variants were extracted which systematically included 1505 non-synonymous variants, 766 synonymous variants, 50 stopgain variants and 3 stop loss variants.
- Blood group associated variants identified in the study are provided as a comprehensive online repository **alnasab**, Alleles and antigens in Arab and Persian populations associated with blood groups. The resource is accessible at https://clingen.igib.res.in/alnasab/

^{\$}Address for correspondence

Abstract

Background

The Middle Eastern population is characterized by increased prevalence of various Mendelian disorders owing to increased rates of consanguinity. Especially in disease conditions which require chronic transfusion support, it becomes important to know the blood group characteristics of potential donors to increase the likelihood of transfusion success. As there prevails a gap in knowledge about the population specific overall blood antigen profiles, this study seeks to utilize next generation sequencing datasets to unravel the comprehensive landscape of clinically significant minor blood group alleles in the middle eastern population.

Methods

This study utilizes the genetic variation data from a range of public datasets including the Greater Middle East Variome, the Qatar genome and exomes and the Iranome datasets to estimate the genotypic and phenotypic frequencies of blood group alleles in the Middle Easterners. The estimated frequencies were duly compared with major global populations to identify significant similarities or differences if any.

Results

A total of 77 unique ISBT approved blood group alleles were found commonly in all datasets. 8 variants (rs8176058, rs1058396, rs565898944, rs28362692, rs2071699, rs34783571, rs60322991 and rs57467915) belonging to KELL, KIDD, COLTON, H, JUNIOR and LANGEREIS blood groups were found clinically significant with previously reported evidence on transfusion complications. 730 variants were found to span exonic or splicing regions out of which 70 were predicted to be potentially deleterious by at least four computational tools.

Conclusions

This study serves first of its kind to extensively characterize the known and novel blood alleles in the Middle Easterners. A comprehensive user-friendly online resource named **alnasab** - **Alleles and antigens in Arab and Persian populations associated with blood groups** was also developed as a dependable reference for future transfusion research. The resource is accessible at https://clingen.igib.res.in/alnasab/

Introduction

Blood group antigens are genetically encoded and currently encompass 44 blood group systems, encoding a total of 349 antigens mapping to 50 genes as recognized and approved by the International Society for Blood Transfusion (ISBT). Complications accompanying blood transfusion events are often induced by blood products which escape serological vigilance. Research over the past decade has widened the scope of genomics in

immunohematology by highlighting the existence of geographical and ethnicity based differences in blood genotype and phenotype frequencies. (1), (2), (3).

The Middle Eastern region situated between Africa, Europe and South Asia is the abode of a population which has been central to our understanding of human evolution, history and migration (4), (5), (6), (7). Encompassing about 17 countries with an estimated population of around 411 million, this region has often remained underrepresented in large global population scale genomic studies. However, with a recent spurt in interest, various population scale sequencing projects have been undertaken aimed at understanding the genomic diversity and architecture of the Arab populations.(8), (9), (10), (11), (12).

Only a limited number of studies have investigated the prevalence of blood group antigens in Middle Eastern populations, primarily focusing on the ABO and RH systems along with few other clinically significant minor blood groups (13), (14), (15), (16), (17). However, these studies have been limited by their use of standard serological testing or medium throughput molecular typing techniques, and therefore there is a paucity of a comprehensive population-specific molecular blood group profile.

It is well established that genetic disorders are a significant burden in the Middle East owing to their increased rates of consanguinity. This has resulted in high prevalence of various autosomal recessive disorders. In particular, genetic blood disorders including Sickle cell disease (SCD) and β -thalassemia, the most common hemoglobinopathies have been reported to substantially contribute to the disease burden of this population (18), (19). A review estimated that the overall incidence and prevalence of SCD in Middle Eastern countries ranged from approximately 0.004% - 2.1% respectively (20). Such inherited blood disorders owing to their chronic nature tend to impose heavy medical, emotional and financial burden. Although the overall burden of such illnesses encompassing various medical aspects of the disease largely remain uncharacterized in Middle Eastern countries, conditions like thalassemia major (TM) and SCD demand long term transfusion therapy.

In recent years, there have been systematic efforts to determine the blood group phenotypes of regular blood donors visiting donation centers in the United Arab Emirates. Advancements in next generation sequencing techniques would undoubtedly enable the large population scale deployment of such efforts in the region. The availability of numerous public Middle Eastern genomic datasets encouraged us to computationally decipher the blood antigen profiles of Middle Easterners as previously described by Schoeman et al in 2019.

In this study we aim to compile a comprehensive collation of blood alleles prevailing in the middle eastern population along with a systematic comparison with other major population datasets including the 1000 Genomes Project and gnomAD. In addition, we developed a user-friendly online resource alnasab - Alleles and antigens in Arab and Persian populations associated with blood groups which is a comprehensive catalog of genetic variants associated with human blood group systems identified in Middle Easterners. The resource is accessible online at https://clingen.igib.res.in/alnasab/

Materials and methods

Population scale genomic datasets

Whole genome and whole exome sequencing datasets generated by population specific studies in the Greater Middle Eastern region were compiled and used for the analysis. This includes data from the Greater Middle East Variome (21), The Qatar genome and exomes (10) and the Iranome (9) genome projects. These accounted for a total of 2828 high quality exomes and 88 genomes (GME: 1111 exomes; Qatar: 88 genomes and 917 exomes; Iranome: 800 exomes), encompassing 689299, 20159694 and 1575702 total genetic variants respectively. The population scale data is a collation of major ethnic groups of the middle eastern region including North Western Africa (NWA), North East Africa (NEA), Arabian Peninsula (AP), Turkish Peninsula (TP), Persia and Pakistan (PP), Syrian Desert (SD), Qatari subgroups and Iranian Arabs, Azeris, Baluchs, Kurds, Lurs, Turkmen and Persians. All the datasets correspond to human genome 19 (GRCh37/hg19) assembly. Genetic variations were retrieved from the variant call format (VCF) files and were used for further analyses.

Human blood group related alleles and variations

Clinically approved genomic coordinates of 50 genes associated with 43 human blood group systems and 2 erythroid specific transcription factors were fetched from Locus Genomic Reference (LRG) (22) and were used for analysis as described previously (23). There exists a handful of public resources that provide comprehensive collection of human blood alleles and antigens including the International Society of Blood Transfusion (ISBT) (24), The Blood Group Antigen Gene Mutation Database (dbRBC) (25), Erythrogene (26) RhesusBase (27), Blood Antigens (28,29) and BGvar (30). A comprehensive list of approved and predicted human blood group alleles were retrieved in a pre-formatted template (30) and was used as the reference data for further allele matching procedures.

Data processing and variant annotations

Primary analysis involved the filtering of all genetic variations spanning the LRG approved genomic coordinates of blood group genes and erythroid specific transcription factors. Subsequently, the filtered variants were systematically annotated for their functional consequences from a range of computational tools including SIFT (31), Polyphen (32), LRT, MutationTaster, Mutation Assessor (33), FATHMM (34), PROVEAN (35), CADD (36), GERP (37), PhyloP (38) and PhastCons using ANNOVAR (v. 2018-04-06) (39).

Known and novel blood group alleles/variants identification

Secondary stages of variant analyses involved the filtering and identification of well known and novel blood group alleles. Reference dataset was used to match all the variants which already had a known associated blood phenotype and reference genome nomenclature was conferred to those blood group systems with no blood group associated variants. In addition, potentially novel and rare blood group variants were also filtered and analyzed. A variant was deemed potentially novel if it lacked previous literature reports and SNP identification number (dbSNP ID). Variants with minor allele frequencies (MAF) < 5% were also filtered and checked for their association with blood group related phenotypes. A complete schematic representation of the workflow is shown in **Figure 1.**

Prediction of blood phenotypes in Qatari subpopulations

The publicly available genomic data of 1005 Qatari individuals comprising 5 major subpopulations were analyzed in the study to decipher the pattern of distribution of blood

phenotypes among the Qatari subpopulations. The variant call file was systematically subsetted into each subpopulation using VCFTOOLS (40). Bespoke scripts were used to generate the number of samples with homozygous and heterozygous genotypes. Similarities and distinct differences in blood alleles and phenotype frequencies were studied. Minor allele frequencies were compared among the subpopulations and statistical significance was observed using Fisher's exact test with a p-value < 0.05.

Estimation and systematic comparison of blood allele frequencies

Blood group associated variants filtered from all the datasets were systematically compiled in variant call or annotated formats along with their genotype information. Allele frequencies were estimated using PLINK {ref}. In addition, allele frequencies of the variants were fetched from major global population datasets including 1000 Genomes project {ref}, Exome Aggregation Consortium (ExAC v.0.3) {ref} and Genome Aggregation Database (gnomAD) {ref} and were used for comparison. Frequency of the filtered alleles among the subpopulations were also calculated.

Identification of clinically significant and actionable blood group alleles

Variants with known blood group associated phenotypes filtered from the datasets were further checked for their clinical relevance in transfusion procedures and in pregnancy settings. Literature databases and public resources like Pubmed and Google scholar were systematically queried to retrieve relevant clinically significant evidence of alleles.

Compendium of Greater Middle East blood group variants - Database architecture
The filtered variants were compiled into a preformatted mastersheet and annotations were
duly mapped. The variant data and corresponding annotations were transformed to
JavaScript Object Notation format and ported onto MongoDB 3.4.1. The user-friendly web
interface for querying the database was coded in PHP 7.0, AngularJS, HTML, Bootstrap 4
and CSS. The web server was configured in Apache HTTP server.

Results

Overview of blood group alleles in Greater Middle East

We retrieved a total 18717 unique variants mapping to 50 human blood group genes, out of which 1697, 15140 and 3496 variants were from the Greater Middle East Variome, The Qatar genome and the Iranome datasets respectively. **Supplementary Table 1** provides a comprehensive summary of all the variant counts in blood group genes fetched from the above mentioned datasets. Of the variants, 2428 and 15 variants were found across exonic and splicing regions respectively. Of these, there were 1505 non synonymous SNVs, 766 synonymous SNVs, 50 stop gain and 3 stop loss variants. Variant summary and functional classifications across the datasets are schematically represented in **Figure 2**.

Characterization of genetic variations in human blood group genes

Of the variants which mapped to the 50 blood group genes, a total of 147, 110 and 112 variants were previously shown to be associated with blood group related phenotypes in GME, Qatar and Iranome datasets respectively. Of these variants, a total of 77 unique variants belonging to 20 blood group systems were overlapping in all three datasets used in this study. The details of the variants along with their frequencies are tabulated in **Table 1**.

Figure 3 illustrates the distribution of these variants and their corresponding allele frequencies in various datasets. Forty-six (46) of the total 77 variants were SNVs mapping back to 16 blood groups and the rest were combination mutations for which blood phenotypes could not be predicted. Phenotypes were reported the same as that of the reference genome (hg19) nomenclature for the rest blood group systems as previously described (41), (23). **Table 2** summarizes the phenotypes of the variants and their corresponding zygosity information across the datasets. Phenotype frequencies of blood group systems with known blood group associated variants and those with reference genome nomenclature are detailed in **Supplementary Table 2**.

Overview of potentially novel and rare blood group variants

Variants were systematically classified based on the dbSNP identifiers and were deemed as potentially novel if they lacked one. This analysis revealed a total of 1727 potentially novel unique variants across the datasets, of which 730 were found to span the exonic and splicing regions. Seventy (70) exonic variants which were not reported previously in global population frequencies including 1000 Genomes, gnomAD and EXAC were predicted to be deleterious by at least three or more computational tools. Distribution of these novel variants across different blood group genes along with their corresponding frequencies in the Middle Eastern datasets are summarized in **Supplementary Table 3.** A missense H blood group variant (p. Arg220Leu, chr19:49253880C>A) which was computationally predicted as deleterious, has a couple of alternate variants reported at the same position associated with weak H+ phenotype (p.Arg220Cys - FUT*01W.09 and p.Arg220His - FUT*01W.10). Yet another missense variant predicted from the same blood group (p. Try154Asp, chr19:49254079A>C) possess reported variants at the same amino acid position associated with weak and null H phenotypes (p.Tyr154Cys - FUT*01N.02, p.Tyr154His - FUT*01W.05.01 and p.Tyr154Ter - FUT*01N.03).

Two missense variants belonging to JUNIOR blood group predicted as deleterious (p.Gly262Glu, chr4:89039317C>T and p.Arg246Leu, chr4:89039365C>A) were found to occur at the same amino acid sites which were reported to be associated with Jr(a-) phenotypes (p.Gly262X - ABCG2*01N.05 and p.Arg246X - ABCG2*01N.03 respectively).

Distribution of null and partial/weak antigens

Weak or partial expression of RBC antigens carries increased risk of hemolytic transfusion reactions as they are often mistyped as antigen-negative. Of the total variants analysed, our study reports 19 variants responsible for weak/partial or null blood group phenotypes. The RHD*weak D type 4.0 allele (rs1053355) was observed in 10 individuals in a homozygous state. This allele, responsible for the weak expression of D antigen, was found to be often mistyped as D- in serological tests (42). In addition, one of the rare low frequency antigens of the RH blood group system, C* (Rh8 - rs138268848) was found in about 0.17% of Middle Eastern populations (0.13% in Iranome and 0.36% in GME). This antigen has been reported to have serious transfusion implications including hemolytic disease of the newborn when mismatched (43).

A weak JK*A allele (JK*01W.01 - rs2298720) of the KIDD blood group system, associated with weakened expression of Jk^a is found capable of causing alloimmunization when mistyped serologically as $Jk_{null\ (44)}$, (45). Distribution of this variant is found to vary highly among various global populations with an allele frequency as high as 40.6% in East Asians,

26.8% in South Asians, 18-19% in Latino/Admixed Americans and African/African Americans, 12% in Europeans of Finnish origin, 10% in Ashkenazi Jews to as low as 7% in Middle Easterners, 6% in Europeans of non-Finnish origins and 3% in Amish population. **Supplementary Table 4** enlists the complete details of weak/partial alleles identified in the study dataset.

Clinically significant blood group variants

The KELL blood group system is significant in the field of transfusion medicine owing to the severe transfusion incompatible reactions induced by its antigens (46). This system comprises over 20 different antigens, of which K1 (K) has been well studied as a strong immunogen capable of causing hemolytic disease of the newborn in sensitized mothers. Approximately 9% of the random RBC donor samples were found to react against K1 (46,47). Anti-K1 is ranked third most clinically significant antibody after ABO and RH(D). HDN induced by anti-K is characterized by immune destruction of K+ erythroid (47) progenitor cells by macrophages in the fetal liver (48). Frequency of this variant in Middle Easterners was found to be 3.5% which was comparable to Europeans of non-Finnish origin (4.1%) and differ from South Asians (<1%) (49), (50)

Anti-Cr^a is a rarely encountered antibody against the Cr(a) antigen of the CROMER blood group system. CROM:c.679G>C (rs60822372) variation in exon 6 of CROM gene is responsible for Cr(a-) phenotype which is characterized by the absence of Cr(a) antigen on the RBC membrane. Studies have shown negative crossmatching of individuals carrying the variant in homozygous state and positive while in heterozygous state (51). This variant was observed at a frequency of about 10% in Middle Eastern populations which was found to be comparable to African/African Americans and South Asians (52), (53),(54).

Blood group phenotyping of Qatari subpopulations

The genomic data of 1005 Qataris comprises 5 major subpopulations namely African (n=70), Arabian (n=193), Bedouin (n=490), Persian (n=170) and South Asian (n=76). Distribution of blood group related variants in different subpopulations was identified and corresponding phenotypes were predicted. In addition, systematic comparisons of allele and phenotype frequencies among the subpopulations were performed.

Comparison and statistical analysis of blood group variants/profiles among Middle Eastern population datasets

Distinct differences in the minor allele frequencies of blood group alleles between the Middle Easterners and various other global populations were statistically estimated using Fisher's exact test. A total of 26 variants mapping back to 12 blood group systems were found statistically distinct in all the Middle Easterners (Qatar, GME and Iranome) in comparison to global datasets (1000 Genomes Project and gnomAD version?). Summary of these variants along with their p-value is provided in **Supplementary Table 5a.** In addition, differences in the pattern of distribution of these blood group variants were checked among the 5 major Qatari subpopulations. The Arabian subpopulation was found to carry the maximum number of variants whose frequencies were statistically distinct from the overall frequency in the Qatar dataset. Complete details of these variants are tabulated in **Supplementary Table 5b.**

User friendly data access

alnasab (Alleles and antigens in Arab and Persian populations associated with blood groups) is a user-friendly online search engine, composed of a comprehensive collection of blood group related variations mined from various population scale datasets of the Greater Middle Eastern region. The resource encompasses a total of 2149 blood group related variants fetched from about 47 blood group genes. The search interface enables the user to query the database based on gene name, variant name (chr-pos:ref>alt), nucleotide change and protein change. Variant information is provided in six different sections namely, (i) Blood group system, (ii) Variant details, (iii) Transcript details, (iv) Variant annotation, (v) Global allele frequencies and (vi) Allele frequencies - Greater Middle East. **Figure 4a and 4b** illustrate the search features and various sections of result display of the resource.

Discussions

Genomic analysis presented in this study provides the blood group genotype profiles of the Middle Eastern populations utilizing the genome sequencing datasets from Greater Middle East Variome, The Qatar genome and the Iranome. The study reports an array of weak, partial, null and putative novel and rare antigens which were predicted to have potential impact on the functionality. The analyzed and filtered blood group variants along with extensive functional annotations and allele frequencies are provided as a comprehensive online repository - **alnasab**, *Alleles and antigens in Arab and Persian populations associated with blood groups*. The resource is accessible at https://clingen.igib.res.in/alnasab/

Clinical impact

An extended screening of blood group antigens between the donors and the recipients other than the major ABO, RH groups and minor DUFFY, KELL and KIDD groups is often triggered only after encountering clinical complications. Frequencies of a total of 26 variants belonging to 12 different blood group systems were found to differ significantly from other global populations. Fetal anaemia and Hemolytic disease of the fetus and newborn (HDFN) are the most serious consequences of transfusion in the majority of pregnancy settings (55). The clinically significant antibodies involved in such cases include Rh, C, E, c and e antigens with greater than 50% risk of mild to severe HDFN (56),(57). Our study reports a weak RHD allele (*RHD*weak D type 4.0*) with an overall frequency of 0.01% in the Middle eastern population. Often patients carrying this allele get serologically categorized to be transfused with D- RBCs. A recent report from a transfusion work group recommendation explained the necessity of RHD molecular genotyping in expectant mothers which would help categorize RHD alleles that can further allow safe D+ transfusion (42).

Literature comparison

There exists a handful of research studies and reports documenting the blood group profiles of donors across various parts of the Arabian peninsula. Phenotypes of ABO, RH and various other minor blood group systems predicted by standard serological methods were found to match with the genotyping profiling results of the study. (50), (58), (58,59), (60), (61). Js^a (KEL6) is a low-incidence antigen reported in less than 1% of the general global populations, whereas on other hand, could be prevalent upto 19.5% in African Americans (62). Js(a+b-) phenotype which was not previously reported in serological studies was found in one sample from North East Africa. In compliance with earlier evidence, frequencies of minor blood group phenotypes including Fy(a+b+), K-k+, Lu(a-b+), Jk(a+b+), Do(a+b+), Co(a+) were found comparable.

Limitations and future needs

Owing to the limitations in the available public datasets, our study is mainly limited by the fact that RBC antigenic expressions regulated by large deletions and insertions (especially in RH and MNS blood groups) have not been profiled. In addition, the level of concordance with serology based phenotype predictions to investigate the functional implications of novel and rare variants remains to be explored and validated in future studies.

Conclusion

Middle Easterners represent one of the most genetically diverse populations with increased prevalence of genetic disorders owing to their consanguinity. Autosomal recessive genetic disorders including sickle cell disease (SCD), beta thalassemia hemoglobinopathies are found to be the most common in the Middle Eastern population (63), (18). Increased burden of anemia in women and children is also reported in this population ranging between 22.6-63% in pregnant women, 27-69.6% in women of reproductive age and 23.8-83.5% in children under age of 5 (64). The overall prevalence rates per 1000 population for beta thalassemia and SCD were found as 13.6 and 49.6 respectively (19). Severe forms of such disorders and other chronic illnesses require frequent blood transfusions often leading to dysfunction of multiple organs, if mismatched (65). Extensive population scale characterization of blood group antigen profiles can significantly increase the clinical outcomes of transfusion practices. Numerous national initiatives including Makkah Region Quality Program (MRQP), Central Board of Accreditation for Health Institutions (CBAHI), The Saudi Food and Drug Authority (SFDA), Western Region Transfusion Medicine Group and Saudi Society of Transfusion Medicine (SSTM) have been organized by the Ministry of Health of Saudi Arabia which aims at improving the blood transfusion services in the region (66). Our study showcases the utility of population scale genome sequencing datasets in elucidating the complete blood antigen profiles of the population to guide and improve transfusion practices and outcomes.

Funding

This work was supported by The Council of Scientific and Industrial Research, India (Grant: MLP2001/GenomeApp)


Acknowledgements

VS conceived and designed the project. MR and VS contributed in writing the manuscript. KP designed the database. All authors approved the final manuscript. Authors acknowledge funding from CSIR India. The funders had no role in the preparation of the manuscript or decision to publish. The authors acknowledge the constructive suggestions given by Srashti Jyoti Agrawal and Vishu Gupta.

Conflicts of Interest

None declared.

Visual abstract



Figures and Tables

- Figure 1. Schematic representation of the methodology followed for data analysis
- **Figure 2.** Overview of the functional classification of blood group related variants in various datasets used in the study
- **Figure 3.** Schematic illustration of the distribution of common variants with blood group associated phenotypes along with their corresponding allele frequencies. (A), Heatmap illustrating the similarities and differences in the allele frequencies among various datasets (B), Distribution of blood group related variants in various datasets used in the study (C) Distribution of common alleles among human blood group systems
- **Figure 4.** Search query and sections of result display in alnasab. (A) Homepage of the web resource with query search examples. (B) Result display which provides an extensive summary of variant functional annotations in various sections
- **Table 1.** Summary of variants with blood group associated phenotypes found commonly in all the Middle Eastern datasets used in the study
- **Table 2.** Summary of phenotypes of common blood group variants along with their corresponding zygosity information




Figure 1. Schematic representation of the methodology followed for data analysis




Figure 2. Overview of the functional classification of blood group related variants in various datasets used in the study




Figure 3. Schematic illustration of the distribution of common variants with blood group associated phenotypes along with their corresponding allele frequencies. (A), Heatmap illustrating the similarities and differences in the allele frequencies among various datasets (B), Distribution of blood group related variants in various datasets used in the study (C) Distribution of common alleles among human blood group systems






Figure 4. Search query and sections of result display in alnasab. Homepage of the web resource with query search examples (top). Result display which provides an extensive summary of variant functional annotations in various sections (bottom)

| CHR | POS | RSID | REF | ALT | BLOOD GROUP SYSTEM | GENE NAME | CATEGO RY | | QATAR_E | IRANOME_ EXOME_AF | EXAC_ AF | gnomA D_AF |
|------|---------------|-----------------|------|-----|--------------------------|--------------|----------------------------------|--------------------|----------|----------------------|--------------|---------------|
| CIIK | 103 | | IXEI | ALI | SISILIN | IVAIVIE | Combinat | | XOWIL_AI | EXOME_AI | | |
| 11 | 837514 | rs1390 42921 | С | Т | RAPH | CD151 | Mutation s | 0.00252 016129 | 0.0064 | 0.000625 | 0.0001 09 | 0.0000 88 |
| 1 | 20750 4467 | rs6082 2373 | G | С | CROMER | CD55 | SNVs | 0.00453 1722054 | 0.006 | 0.00125 | 0 | 0 |
| 1 | 207760 773 | rs3737 002 | С | Т | KNOPS | CR1 | SNVs | 0.22205 43807 | 0 | 0.24875 | 0.2750 08 | 0.2824 56 |
| 1 | 207782 856 | rs1704 7660 | А | G | KNOPS | CR1 | SNVs | 0.02970 795569 | 0 | 0.0025 | 0.02141 1 | 0.01815 6 |
| 1 | 207782 889 | rs1704 7661 | А | G | KNOPS | CR1 | SNVs | 0.07552 870091 | 0 | 0.011875 | 0.0548 3 | 0.0460 45 |
| 1 | 207782 931 | rs66911 17 | А | G | KNOPS | CR1 | SNVs | 0.32426 98892 | 0 | 0.33875 | 0.3341 07 | 0.3213 6 |
| 12 | 149938 82 | rs2836 2798 | G | A | DOMBROCK | ART4 | SNVs | 0.00805 6394763 | 0.007 | 0.001875 | 0 | 0 |
| 12 | 149939 09 | rs2836 2797 | С | A | DOMBROCK | ART4 | Combinat ion Mutation s | 0.00604 2296073 | 0.0032 | 0.000625 | 0.0050 74 | 0.0039 38 |
| 1 | 256110 80 | rs23011 55 | С | Т | RH | RHD | SNVs | 0.00753 4983854 | 0.0133 | 0.00721785 | 0.0007 44 | 0.0008 14 |
| 1 | 256111 01 | rs1995 09194 | G | Т | RH | RHD | Combinat ion Mutation s | 0.01885 775862 | 0.0048 | 0.00197109 | 0.0066 53 | 0.0055 86 |
| 1 | 256172 06 | rs11398 2491 | С | Т | RH | RHD | SNVs | 0.00371 5498938 | 0.0059 | 0.0026560 4 | 0.0066 54 | 0.0057 81 |
| 1 | 256172 51 | rs17418 085 | A | С | RH | RHD | Combinat ion Mutation s | 0.00641 7112299 | 0 | 0.0026809 7 | 0.0066 27 | 0.0054 44 |
| 1 | 256275 52 | rs1053 355 | С | G | RH | RHD | SNVs | 0.01397 849462 | 0 | 0.0053404 5 | 0.0050 9 | 0.0046 95 |
| 1 | 25628 043 | rs1053 356 | Т | G | RH | RHD | SNVs | 0.02355 460385 | 0.0171 | 0.0060402 7 | 0.01211 4 | 0.0103 46 |
| 1 | 25628 050 | rs14801 4996 | С | Т | RH | RHD | Combinat ion Mutation s | 0.00319 8294243 | 0.0064 | 0.00134048 | 0.0040 99 | 0.0034 47 |
| 1 | 25628 073 | rs1053 359 | G | С | RH | RHD | SNVs | 0.00373 5325507 | 0.0047 | 0.00201072 | 0 | 0 |
| 1 | 256281 20 | rs1053 362 | С | Т | RH | RHD | SNVs | 0.00482 3151125 | 0.0021 | 0.0026738 | 0.0011 82 | 0.0010 57 |
| 1 | 256298 18 | rs14183 3592 | Т | G | RH | RHD | SNVs | 0.002212 389381 | 0.0065 | 0.00134953 | 0.0045 2 | 0.0033 |
| 1 | 256298 30 | rs1506 06530 | G | А | RH | RHD | SNVs | 0.011615 04425 | 0.0041 | 0.0026845 6 | 0.0042 9 | 0.0035 32 |
| 1 | 256331 04 | rs1462 92192 | G | А | RH | RHD | SNVs | 0.00423 7288136 | 0.0021 | 0.0026809 7 | 0.0005 72 | 0.0005 91 |
| 1 | 256331 72 | rs1382 35491 | Т | С | RH | RHD | SNVs | 0.00477 7070064 | 0.0021 | 0.00266312 | 0.0006 09 | 0.0006 39 |
| 1 | 25648 421 | rs1500 59028 | G | A | RH | RHD | SNVs | 0.00826 9018743 | 0.0158 | 0.0087956 7 | 0.0041 84 | 0.0043 62 |

| 1 | 257122 69 | rs11626 1244 | С | A | RH | RHCE | SNVs | 0.00100 7049345 | 0 | 0.00125 | 0.0035 | 0.0028 71 |
|----|--------------|-----------------|---|---|----------|---------|----------------------------------|-------------------------|--------|-----------|--------------|--------------|
| 1 | 257154 90 | rs11327 65 | T | С | RH | RHCE | SNVs | 0 | 0.0016 | 0.001875 | 0.0005 12 | 0.0004 66 |
| 1 | 257173 08 | rs1053 361 | G | С | RH | RHCE | SNVs | 0.06344 410876 | 0.0368 | 0.008125 | 0.02271 9 | 0 |
| 1 | 257173 29 | rs14416 3296 | Т | С | RH | RHCE | SNVs | 0.00402 8197382 | 0.0035 | 0.001875 | 0.0013 43 | 0.0009 51 |
| 1 | 257173 65 | rs6093 20 | С | G | RH | RHCE | SNVs | 0.12990 93656 | 0.1716 | 0.161875 | 0.16218 6 | 0.1690 06 |
| 1 | 257292 12 | rs1053 345 | Т | _ | RH | RHCE | SNVs | 0.00050 3524672 7 | 0.0006 | 0.006875 | 0.0019 | 0.0017 86 |
| 1 | + | - | G | C | RH | RHCE | SNVs | 0.00541 5162455 | 0.0008 | 0.000875 | 0 | 0 |
| 1 | 257471 56 | rs1382 68848 | Т | С | RH | RHCE | SNVs | 0.00850 3401361 | 0.0022 | 0.00875 | 0.0108 | 0.0102 45 |
| 1 | 257471 73 | rs14297 1926 | G | A | RH | RHCE | SNVs | 0.00902 | 0.0035 | 0.000625 | 0 | 0 |
| 15 | 747039 29 | rs74176 | Т | С | ЈМН | SEMA7A | Combinat ion Mutation s | 0.431017 1198 | 0.4922 | 0.431875 | 0 | 0 |
| 18 | 433103 13 | rs11357 8396 | G | A | KIDD | SLC14A1 | Combinat ion Mutation s | 0.02769 3857 | 0.026 | 0.009375 | 0.0065 67 | 0 |
| 18 | 433104 15 | rs2298 720 | G | A | KIDD | SLC14A1 | Combinat ion Mutation s | 0.121852 9708 | 0.0796 | 0.1375 | 0.1474 59 | 0.15195 6 |
| 18 | 433110 54 | rs11302 9149 | G | A | KIDD | SLC14A1 | Combinat ion Mutation s | 0.02923 387097 | 0.0299 | 0.009375 | 0.0081 22 | 0.0069 |
| 18 | 433111 31 | rs2899 4287 | G | А | KIDD | SLC14A1 | Combinat ion Mutation s | 0.029471 54472 | 0 | 0.009375 | 0.0078 85 | 0.0066 44 |
| 18 | 433164 61 | rs9948 825 | T | С | KIDD | SLC14A1 | SNVs | 0.001510 574018 | 0 | 0.000625 | 0.0015 07 | 0.00115 |
| 18 | 433165 38 | rs2298 718 | A | G | KIDD | SLC14A1 | Combinat ion Mutation s | 0.573011 0775 | 0.4562 | 0.590625 | 0.3642 7 | 0.3618 46 |
| 18 | 433192 74 | rs1767 5299 | G | А | KIDD | SLC14A1 | SNVs | 0.03675 730111 | 0 | 0.053125 | 0 | 0 |
| 18 | 433195 19 | rs1058 396 | G | А | KIDD | SLC14A1 | SNVs | 0.40584 08862 | 0.3323 | 0.439375 | 0.4695 4 | 0.4714 67 |
| 18 | 433283 50 | rs5658 98944 | С | Т | KIDD | SLC14A1 | SNVs | 0 | 0 | 0.0025 | 0.0006 51 | 0.0006 6 |
| 18 | 433298 41 | rs2889 8897 | Т | С | KIDD | SLC14A1 | Combinat ion Mutation s | 0.017623 36354 | 0.0264 | 0.010625 | 0.0045 47 | 0.0046 67 |
| 19 | 129967 40 | | A | G | KLF1 | KLF1 | Combinat ion Mutation s | 0.29627 71458 | 0.2835 | 0.325448 | 0.4392 1 | 0.3685 99 |
| 19 | 453154 45 | rs2839 9653 | G | A | LUTHERAN | ВСАМ | Combinat ion Mutation s | 0.01209 677419 | 0 | 0.0131579 | 0 | 0 |

| | | | | | | | 0 | | | | | |
|----|---------------|-----------------|---|---|-----------|--------------|----------------------------------|--------------------|--------|----------|--------------|--------------|
| | | | | | | | Combinat ion | | | | | |
| 19 | 453155 39 | rs3745 159 | G | А | LUTHERAN | ВСАМ | Mutation s | 0.02620 967742 | 0.0278 | 0.02875 | 0.0234 69 | 0.0215 |
| 19 | 453167 04 | rs2839 9656 | Т | А | LUTHERAN | BCAM | SNVs | 0.02769 3857 | 0.035 | 0.020025 | 0.0095 57 | 0.0094 85 |
| 19 | 453168 04 | rs38101 41 | С | Т | LUTHERAN | ВСАМ | Combinat ion Mutation s | 0.07703 927492 | 0.0682 | 0.1025 | 0.0879 96 | 0.0862 07 |
| 19 | 453168 07 | rs38101 40 | С | Т | LUTHERAN | ВСАМ | Combinat ion Mutation s | 0.07552 870091 | 0.0661 | 0.1025 | 0.0856 24 | 0.0841 |
| | | | - | | | | Combinat | | | | | - |
| 19 | 453223 16 | rs11773 7673 | С | Т | LUTHERAN | BCAM | ion Mutation s | 0.01560 926485 | 0.0095 | 0.02375 | 0.0222 28 | 0.0210 63 |
| 19 | 453227 44 | rs11350 62 | A | G | LUTHERAN | ВСАМ | Combinat ion Mutation s | 0.330312 1853 | 0.2964 | 0.275 | 0.2753 29 | 0.2725 9 |
| 19 | 453228 91 | rs2839 9658 | С | Т | LUTHERAN | ВСАМ | Combinat ion Mutation s | 0.03776 435045 | 0.0643 | 0.0575 | 0.0315 62 | 0.0296 53 |
| 19 | 453229 62 | rs2839 9659 | A | Т | LUTHERAN | ВСАМ | Combinat ion Mutation s | 0.03850 050659 | 0.066 | 0.055625 | 0.0348 72 | 0.0297 57 |
| 19 | 49254 504 | rs2071 699 | G | A | н | FUT1 | SNVs | 0.041792 54783 | 0.0462 | 0.065625 | 0.0578 46 | 0.0590 25 |
| 2 | 22008 0845 | rs6032 2991 | С | Т | LANGEREIS | ABCB6 | SNVs | 0.008611 95542 | 0.0201 | 0.00125 | 0.01911 | 0.0109 4 |
| 2 | 220081 416 | rs5746 7915 | G | A | LANGEREIS | АВСВ6 | SNVs | 0.00405 2684904 | 0.0006 | 0.000625 | 0.0189 5 | 0.0087 83 |
| 22 | 43088 971 | rs9623 659 | С | Т | P1PK | A4GALT | Combinat ion Mutation s | 0.41683 46774 | 0.4468 | 0.340625 | 0.3523 91 | 0.3503 11 |
| 22 | 43089 849 | rs11541 159 | Т | С | P1PK | A4GALT | SNVs | 0.41809 909 | 0.4485 | 0.341875 | 0.3867 | 0.3491 5 |
| 3 | 160804 167 | rs22312 57 | С | Т | GLOB | B3GALNT 1 | SNVs | 0.04833 836858 | 0.0711 | 0.06 | 0.0456 55 | 0.0448 4 |
| 4 | 144920 596 | rs7683 365 | G | A | MNS | GYPB | Combinat ion Mutation s | 0.33383 6858 | 0 | 0.360625 | 0.3456 92 | 0 |
| 4 | 890134 96 | | С | Т | JUNIOR | ABCG2 | SNVs | 0.00860 3238866 | | 0.0175 | 0.0055 56 | 0.0052 04 |
| 4 | 89052 323 | rs22311 42 | G | Т | JUNIOR | ABCG2 | Combinat ion Mutation s | 0.05186 304129 | 0.0517 | 0.07625 | 0.11801 7 | 0.1246 55 |
| 4 | 890611 14 | rs22311 37 | С | Т | JUNIOR | ABCG2 | Combinat ion Mutation s | 0.106243 7059 | 0 | 0.11125 | 0.1075 81 | 0.11418 9 |
| 6 | 105867 27 | rs5610 6312 | G | А | 1 | GCNT2 | SNVs | 0.002517 623364 | 0.0043 | 0.0025 | 0 | 0 |
| 6 | 49580 247 | rs1687 9498 | С | Т | RHAG | RHAG | Combinat ion Mutation s | 0.05945 121951 | 0 | 0.036875 | 0.0434 54 | 0.0420 61 |

| 7 | 142640 004 | rs8176 039 | Т | С | KELL | KEL | Combinat ion Mutation s | 0.02416 918429 | 0.0328 | 0.0075 | 0.0209 58 | 0.0173 51 |
|---|---------------|-----------------|---|---|---------|-------|----------------------------------|--------------------|--------|----------|--------------|--------------|
| 7 | 142640 113 | rs8176 038 | А | G | KELL | KEL | SNVs | 0.011077 5428 | 0 | 0.001875 | 0.0083 55 | 0.0067 38 |
| 7 | 142640 596 | rs8176 036 | Т | G | KELL | KEL | Combinat ion Mutation s | 0.03373 615307 | 0.0274 | 0.02125 | 0.0528 12 | 0.0504 72 |
| 7 | 142640 916 | rs8176 034 | G | Т | KELL | KEL | SNVs | 0.02668 680765 | 0 | 0.003125 | 0 | 0 |
| 7 | 142641 752 | rs1908 90637 | G | А | KELL | KEL | SNVs | 0.001510 574018 | 0 | 0.0025 | 0.0002 16 | 0.0002 11 |
| 7 | 142651 354 | rs8176 059 | G | A | KELL | KEL | Combinat ion Mutation s | 0.00352 4672709 | 0.0023 | 0.0025 | 0.0071 | 0.0069 76 |
| 7 | 142655 008 | rs8176 058 | G | A | KELL | KEL | Combinat ion Mutation s | 0.04481 369587 | 0.0478 | 0.03125 | 0.0274 38 | 0.0268 98 |
| 7 | 309516 58 | rs2836 2692 | С | Т | | AQP1 | SNVs | 0.00805 6394763 | 0.004 | 0.005625 | 0.0264 68 | 0 |
| 7 | 309516 64 | rs3775 06522 | A | G | | AQP1 | SNVs | 0.00201 4098691 | 0.0011 | 0.004375 | 0.0001 91 | 0.0001 99 |
| 9 | 136029 645 | rs3589 8523 | G | Т | FORS | GBGT1 | SNVs | 0.09182 643794 | 0.1328 | 0.1 | 0 | 0 |
| 9 | 136037 742 | rs2073 924 | G | A | FORS | GBGT1 | SNVs | 0.222557 9053 | 0.2193 | 0.232704 | 0.27771 1 | 0.11379 3 |
| 9 | 136136 773 | rs8176 696 | С | Т | АВО | ABO | SNVs | 0.01359 516616 | 0 | 0.009375 | 0 | 0 |
| 1 | 43296 572 | rs3395 4154 | С | Т | SCIANNA | ERMAP | Combinat ion Mutation s | 0.00856 8548387 | 0.0037 | 0.000625 | 0.0081 39 | 0.0063 98 |

Table 1. Summary of variants with blood group associated phenotypes found commonly in all the Middle Eastern datasets used in the study

| BLOOD GROUP | CHR | POS | RSID | REF | ALT | GENE NAME | PHENOTYPE DESCRIPTION | VARIAN T TYPE | QAT AR HO M COU NT | QAT AR HET COU NT | IRANO ME HOM COUNT | IRANO ME HET COUNT | GME HOM COUN T | GME HET |
|----------------|-----|-------------------|---------------------|-----|-----|--------------|-------------------------------|---------------------------------|-----------------------------------|-------------------------------|-----------------------------|--------------------------|-------------------------|---------|
| RAPH | 11 | 837 514 | rs13 904 2921 | С | Т | CD151 | RAPH:- 1 or MER2- | Combin ation mutatio n | | | 0 | 2 | 0 | 5 |
| CROMER | 1 | 207 504 467 | rs60 822 373 | G | С | CD55 | Cr(a-) - Altered phenotype | SNVs | 1 | 9 | 0 | 2 | 1 | 7 |
| | 1 | 207 760 773 | rs37 370 02 | С | Т | CR1 | Yk(a-) | SNVs | 4 | 27 | 53 | 292 | 74 | 293 |
| KNOPS | 1 | 207 782 856 | rs17 047 660 | A | G | CR1 | McC(b+) | SNVs | 1 | 3 | 0 | 4 | 7 | 45 |
| | 1 | 207 782 889 | rs17 047 661 | A | G | CR1 | Vil+ | SNVs | 4 | 10 | 1 | 17 | 17 | 116 |

| | 1 | 207 782 | rs66 9111 | _ | _ | CD1 | KCAM | CNIV _C | 15 | 26 | 107 | 220 | 124 | 306 |
|--------|----|------------------|-------------------------|---|---|------|---|---------------------------------|----|----|-----|-----|-----|-----|
| | 1 | 931 | 7 rs28 | Α | G | CR1 | KCAM- | SNVs Combin ation | 15 | 36 | 107 | 328 | 124 | 396 |
| DOMBRO | 12 | 938 82 | 362 798 | G | Α | ART4 | DO:-5 or Jo(a-) | mutatio n | 0 | 14 | 0 | 3 | 1 | 14 |
| СК | 12 | 149 939 09 | rs28 362 797 | С | A | ART4 | DO:-4 or Hy Combination mutation with rs11276 | SNVs | 0 | 6 | 0 | 1 | 0 | 12 |
| | 1 | 256 110 80 | rs23 0115 5 | С | Т | RHD | Weak D expression - Combination with 25648439 pos | Combin ation mutatio n | 1 | 23 | 0 | 11 | 0 | 14 |
| | 1 | 256 1110 1 | rs19 950 9194 | G | Т | RHD | | Combin ation mutatio n | 2 | 5 | 1 | 1 | 1 | 33 |
| | 1 | 256 172 06 | rs113 982 491 | С | Т | RHD | Del or weak D | Combin ation mutatio n | 3 | 5 | 1 | 2 | 2 | 3 |
| | 1 | 256 172 51 | rs17 418 085 | A | С | RHD | | Combin ation mutatio n | 2 | 8 | 1 | 2 | 4 | 4 |
| | 1 | 256 275 52 | rs10 533 55 | С | G | RHD | RHD*01W.40 - Weak D expression | SNVs | 0 | 3 | 2 | 4 | 8 | 10 |
| | 1 | 256 280 43 | rs10 533 56 | Т | G | RHD | RHD*08.01 | SNVs | 6 | 20 | 2 | 5 | 12 | 20 |
| | 1 | 256 280 50 | rs14 801 499 6 | С | Т | RHD | | Combin ation mutatio n | 1 | 10 | 1 | 0 | 2 | 2 |
| RH | 1 | 256 280 73 | rs10 533 59 | G | С | RHD | RHD*05.04/RH D*05.05 | SNVs | 1 | 6 | 0 | 3 | 1 | 5 |
| | 1 | 256 281 20 | rs10 533 62 | С | Т | RHD | | Combin ation mutatio n | 0 | 4 | 1 | 2 | 1 | 7 |
| | 1 | 256 298 18 | rs141 833 592 | Т | G | RHD | RHD*01N.18 (D negative) | SNVs | 1 | 10 | 1 | 0 | 2 | 1 |
| | 1 | 256 298 30 | rs15 060 653 0 | G | A | RHD | | Combin ation mutatio n | 2 | 3 | 1 | 2 | 7 | 7 |
| | 1 | 256 331 04 | rs14 629 2192 | G | А | RHD | | Combin ation mutatio n | 0 | 4 | 1 | 2 | 2 | 4 |
| | 1 | 256 331 72 | rs13 823 5491 | | С | RHD | | Combin ation mutatio n | 0 | 4 | 1 | 2 | 2 | 5 |
| | 1 | 256 | rs15 005 902 8 | G | A | RHD | RHD*01W.45 Weak D expression | SNVs | 10 | 7 | 1 | 11 | 3 | 9 |
| | 1 | 257 122 69 | rs11 6261 244 | С | A | RHCE | | Combin | 0 | 3 | 0 | 2 | 0 | 2 |

| | | | | | | | | mutatio | | | | | | |
|------|----|------------------|-------------------------|---|---|-------------|---|---------------------------------|-----|-----|-----|-----|-----|-----|
| | | | | | | | | n | | | | | | |
| | 1 | 257 154 | rs113 276 | _ | | DUGE | | Combin ation mutatio | | 2 | | 2 | | |
| | 1 | 90 257 | 5 rs10 | Т | С | RHCE | | n | 0 | 3 | 0 | 3 | 0 | 0 |
| | 1 | 173 08 | 533 61 | G | С | RHCE | c+ partial e+ partial/ C+e+ | SNVs | 5 | 64 | 0 | 13 | 17 | 92 |
| | | 257 173 | rs14 4163 | | | | | Combin ation mutatio | | | | | | |
| | 1 | 29 | 296 | Т | С | RHCE | | n | 0 | 7 | 0 | 3 | 0 | 8 |
| | 1 | 257 173 65 | rs60 932 0 | С | G | RHCE | | Combin ation mutatio n | 28 | 289 | 23 | 213 | 26 | 206 |
| | 1 | 257 292 12 | rs10 533 45 | Т | А | RHCE | | Combin ation mutatio n | 0 | 1 | 1 | 9 | 0 | 1 |
| | 1 | 257 352 55 | rs57 992 529 | G | С | RHCE | e+ weak partial | SNVs | 1 | 1 | 0 | 1 | 4 | 1 |
| | 1 | 257 471 56 | rs13 826 884 8 | Т | С | RHCE | RH:8 (Cw+) or partial C+ partial e+ RH:8 (Cw+) RH:-51(MAR-) | SNVs | 0 | 7 | 1 | 12 | 4 | 7 |
| | 1 | 257 471 73 | rs14 2971 926 | G | A | RHCE | | | 0 | 7 | 0 | 1 | 0 | 16 |
| ЈМН | 15 | 747 039 29 | rs74 1761 | Т | С | SEMA7 | JMH: -7 or JMHN Combination with rs140707085 and rs140128092 | Combin ation mutatio n | 214 | 397 | 167 | 357 | 207 | 442 |
| | 18 | 433 103 13 | rs113 578 396 | | A | SLC14A | Jk(a+W) ; Jk(a+W - Combination with rs113029149 ; JK:-3 or Jk(a-b-) - Combination with rs113029149, rs28994287 and rs2298718 | SNVs | 2 | 48 | 0 | 15 | 6 | 43 |
| KIDD | 18 | 433 104 15 | rs22 987 20 | G | А | SLC14A | Jk(a+W); Jk(b+W); JK:-3 or Jk(a-b-) - Combination mutation | SNVs | 16 | 128 | 19 | 182 | 31 | 180 |
| | 18 | 433 110 54 | rs113 0291 49 | | A | SLC14A | Jk(a+W); Jk(a+W) - Combination with rs113578396; Jk(a-b-) - Combination with rs113578396, rs28994287 and rs2298718 | SNVs | 2 | 56 | 0 | 15 | 5 | 48 |
| | 18 | | rs28 994 287 | G | А | SLC14A 1 | JK:-3 or Jk(a-b-) - Combination | Combin ation | 0 | 4 | 0 | 15 | 7 | 44 |

| | | | | | | | with rs113578396, rs113029149 and rs2298718 | mutatio n | | | | | | |
|--------------|----|------------------|-------------------------|---|---|-------------|---|---------------------------------|-----|-----|-----|-----|-----|-----|
| | 18 | 433 164 61 | rs99 488 25 | Т | С | SLC14A 1 | Jk(a+W | SNVs | 0 | 1 | 0 | 1 | 0 | 3 |
| | 18 | 433 165 38 | rs22 9871 8 | A | G | SLC14A | Jk(a+W); Jk(b+W); JK:-3 or Jk(a-b-) - Combination mutation | SNVs | 229 | 459 | 283 | 379 | 369 | 400 |
| | 18 | 433 192 74 | rs17 675 299 | G | A | SLC14A | JK:-3 or Jk(a-b-) - Combination with rs113578396, rs113029149 and rs2298718 | SNVs | 0 | 3 | 2 | 81 | 9 | 55 |
| | 18 | 433 1951 9 | | G | А | SLC14A 1 | | SNVs | 123 | 422 | 166 | 371 | 192 | 422 |
| | 18 | 433 283 50 | rs56 589 894 4 | С | Т | SLC14A | JK:-3 or Jk(a-b-); JK:-3 or Jk(a-b-). Both JK*01 and JK*02 | SNVs | 0 | 1 | 0 | 4 | 0 | 0 |
| | 18 | 433 298 41 | rs28 898 897 | Т | С | SLC14A | Jk(b+W) - Combination mutation with rs774982134 | Combin ation mutatio n | 1 | 51 | 2 | 13 | 5 | 25 |
| KLF1 | 19 | 129 967 40 | rs20 725 97 | A | G | KLF1 | *Obsolete* Normal BG phenotype; In(Lu) - Combination mutation; | Obsolet e mutatio n | 83 | 346 | 86 | 337 | 125 | 323 |
| | 19 | 453 154 45 | rs28 399 653 | G | A | ВСАМ | LU:1 or Lu(a+); LU:-16 - Combination mutation; LU:1,19 - Combination mutation | SNVs | 0 | 1 | 1 | 19 | 2 | 20 |
| | 19 | 453 155 39 | rs37 4515 9 | G | A | всам | LU:-27, LUYA Combination mutation | Combin ation mutatio n | 1 | 53 | 2 | 42 | 3 | 46 |
| | 19 | 453 167 04 | rs28 399 656 | Т | А | всам | LU:-8,14 | SNVs | 2 | 65 | 0 | 32 | 4 | 47 |
| LUTHER AN | 19 | | rs38 1014 1 | С | Т | всам | | SNVs | 10 | 114 | 9 | 146 | 15 | 123 |
| | 19 | | rs38 1014 0 | С | Т | ВСАМ | LU:-24, LUGA Combination mutation | Combin ation mutatio n | 9 | 112 | 9 | 146 | 15 | 120 |
| | 19 | 453 223 16 | | С | Т | BCAM | LU:-13 - Combination mutation ; Lu(b+w) - Combination mutation | Combin ation mutatio n | 1 | 17 | 0 | 38 | 4 | 23 |
| | 19 | | rs113 506 2 | A | G | всам | LU:1,19 - Combination mutation; LU:-18,19 or | SNVs | 94 | 390 | 67 | 306 | 130 | 396 |

| | | | | | | | 1 | | | | | | | |
|--------|----|-------------------|--------------------|---|---|--------------|---|---------------------------------|-----|-----|-----|-----|-----|-----|
| | | | | | | | Au(a-b+); LU:-18,19,-8,14 - Combination mutation | | | | | | | |
| | 19 | 453 228 91 | rs28 399 658 | С | Т | ВСАМ | Lu(b+w); LU:-13 - Combination mutations | | 5 | 116 | 1 | 90 | 5 | 65 |
| | 19 | 453 229 62 | rs28 399 659 | Α | Т | ВСАМ | Lu(b+w); LU:-13 - Combination mutations | | 5 | 114 | 1 | 87 | 8 | 60 |
| Н | 19 | 492 545 04 | rs20 7169 9 | G | A | FUT1 | H+ | SNVs | 3 | 86 | 3 | 99 | 5 | 73 |
| LANGER | 2 | 220 080 845 | rs60 322 991 | С | Т | АВСВ6 | Lan weak | SNVs | 0 | 33 | 0 | 2 | 1 | 15 |
| EIS | 2 | 220 081 416 | rs57 467 915 | G | A | АВСВ6 | Lan weak | SNVs | 0 | 1 | 0 | 1 | 0 | 8 |
| P1PK | 22 | 430 889 71 | rs96 236 59 | С | Т | A4GAL T | p - Combination mutation | Combin ation mutatio n | 208 | 466 | 89 | 367 | 198 | 431 |
| | 22 | 430 898 49 | rs11 5411 59 | Т | С | A4GAL T | P1+/-, Pk+ | SNVs | 211 | 466 | 90 | 367 | 193 | 441 |
| GLOB | 3 | 160 804 167 | rs22 3125 7 | С | Т | B3GAL NT1 | GLOB:1 (P+) | SNVs | 6 | 131 | 5 | 86 | 6 | 84 |
| MNS | 4 | 144 920 596 | rs76 833 65 | G | А | GYPB | MNS:3 or S+ | SNVs | 12 | 43 | 111 | 355 | 128 | 407 |
| | 4 | 890 134 96 | rs34 783 571 | С | Т | ABCG2 | Jr(a+w) | SNVs | 0 | 13 | 1 | 26 | 1 | 15 |
| JUNIOR | 4 | 890 523 23 | rs22 3114 2 | G | Т | ABCG2 | Jr(a+w) ; Jr(a-) - Combination mutation | Combin ation mutatio n | 3 | 98 | 5 | 112 | 9 | 85 |
| | 4 | 890 6111 4 | rs22 3113 7 | С | Т | ABCG2 | Jr(a-) - Combination mutation; | Combin ation mutatio n | 0 | 16 | 7 | 164 | 19 | 173 |
| ı | 6 | 105 | rs56 1063 12 | G | A | GCNT2 | I+W | Combin ation mutatio n | 1 | 6 | 0 | 4 | 0 | 5 |
| RHAG | 6 | 495 802 47 | rs16 | С | Т | RHAG | Rhnull - Combination mutation | Combin ation mutatio n | 0 | 7 | 2 | 55 | 12 | 93 |
| | 7 | 142 640 004 | | Т | С | KEL | Kmod - Combination mutation | Combin ation mutatio n | 5 | 56 | 0 | 12 | 3 | 42 |
| KELL | 7 | 142 640 113 | rs81 760 38 | A | G | KEL | KEL:6,-7 or Js(a+b-) | SNVs | 0 | 3 | 0 | 3 | 1 | 20 |
| | 7 | 142 640 596 | | Т | G | KEL | Kmod - Combination mutation | Combin ation mutatio n | 1 | 53 | 1 | 32 | 3 | 61 |

| ı | | | | | | | | | | | | | | |
|-------------|---|-------------------|-------------------------|---|---|-------|--|---------------------------------|----|-----|----|-----|----|-----|
| | 7 | 142 640 916 | rs81 760 34 | G | Т | KEL | KEL:2 or k+/Ko | SNVs | 0 | 3 | 0 | 5 | 5 | 43 |
| | 7 | 142 641 752 | rs19 089 063 7 | G | A | KEL | KEL:-36 or KETI- | SNVs | 0 | 1 | 0 | 4 | 0 | 3 |
| | 7 | 142 651 354 | rs81 760 59 | G | A | KEL | KEL:1weak,3 or K+w, Kp(a+) - Combined with rs8176058; KEL:3,-4,-21 or Kp(a+b-c-); KO - Combined with rs1268359042; Kmod - Combined with rs777011308 | SNVs | 0 | 4 | 0 | 4 | 0 | 7 |
| | 7 | 142 655 008 | rs81 760 58 | G | A | KEL | KEL:1,-2 or K+k-; KEL:1weak,3 or K+w, Kp(a+) - Combined with rs8176059; K0 - Combination mutation; Kmod - Combination mutation | SNVs | 4 | 88 | 1 | 48 | 4 | 81 |
| | 7 | 309 516 58 | rs28 362 692 | С | Т | AQP1 | CO:2 or Co(b+) | SNVs | 0 | 8 | 0 | 9 | 0 | 16 |
| COLTON | 7 | 309 516 64 | rs37 750 652 2 | A | G | AQP1 | CO:-1,-2,3,-4 | SNVs | 0 | 2 | 1 | 5 | 0 | 4 |
| FORC | 9 | 136 029 645 | rs35 898 523 | G | Т | GBGT1 | FORS:-1 (FORS-) | SNVs | 22 | 223 | 7 | 146 | 22 | 138 |
| FORS | 9 | 136 037 742 | rs20 739 24 | G | A | GBGT1 | FORS:-1 (FORS-) | SNVs | 44 | 341 | 53 | 264 | 61 | 320 |
| ABO | 9 | 1361 367 73 | rs81 766 96 | С | Т | АВО | | Combin ation mutatio n | 0 | 2 | 0 | 15 | 0 | 27 |
| SCIANN A | 1 | 432 965 72 | rs33 9541 54 | С | Т | ERMAP | SC:-9 or SCAC- - Combination mutation | SNVs | 0 | 7 | 0 | 1 | 2 | 13 |

Table 2. Summary of phenotypes of common blood group variants along with their corresponding zygosity information

Supplementary Datasets

Supplementary Table 1. Brief tabulation of number of variants found associated with human blood group genes in the datasets used in the study.

Summary of blood group variants in study datasets

Supplementary Table 2. Tabulation of blood group alleles predicted to match ISBT approved phenotypes and reference genome nomenclature in Middle Eastern population datasets

Predicted phenotypes of blood group systems in Middle Eastern population

Supplementary Table 3. Summary of distribution of novel and rare blood group variants in GME datasets predicted to be deleterious by at least three or more computational tools.

Tabulation of potentially novel and deleterious blood group variants in GME datasets

Supplementary Table 4. Comprehensive tabulation of weak/partial or null allele variants found in Middle Eastern populations along with their zygosity information.

Summary of weak or partial antigens identified in the study dataset


Supplementary Table 5a. Summary of statistically distinct blood group variants identified between the Middle East and global population datasets

<u>Distinct blood group variants between the Middle East and global populations</u>

Supplementary Table 5b. Summary of statistically distinct blood group variants observed among the Qatari subpopulations

Distinct blood group variants among Qatari subpopulations

Supplementary Figure 1. Distribution of statistically distinct blood group variants in various Middle Eastern datasets and among Qatari subpopulations



Supplementary Figure 1. Distribution of statistically distinct blood group variants. (A) Summary of blood group variants which were found statistically distinct in various Middle Eastern datasets in comparison to global population data. (B) Distribution of statistically distinct blood group variants among the major Qatari subpopulations in comparison to the overall Qatar frequencies.

References

- 1. Seltsam, A. and Doescher, A. (2009) Sequence-Based Typing of Human Blood Groups. Sequence-Based Typing of Human Blood Groups. *Transfusion Medicine and Hemotherapy* (2009), 36, 204–212.
- 2. Reid, M.E. (2007) Overview of molecular methods in immunohematology. *Transfusion*, **47**, 10S–6S.
- 3. Liu, Z., Liu, M., Mercado, T., Illoh, O. and Davey, R. (2014) Extended blood group molecular typing and next-generation sequencing. *Transfus. Med. Rev.*, **28**, 177–186.
- 4. Hershkovitz, I., Weber, G.W., Quam, R., Duval, M., Grün, R., Kinsley, L., Ayalon, A., Bar-Matthews, M., Valladas, H., Mercier, N., et al. (2018) The earliest modern humans outside Africa. *Science*, **359**, 456–459.
- 5. Groucutt, H.S., Grün, R., Zalmout, I.A.S., Drake, N.A., Armitage, S.J., Candy, I., Clark-Wilson, R., Louys, J., Breeze, P.S., Duval, M., et al. (2018) Homo sapiens in Arabia by 85,000 years ago. Nat Ecol Evol, **2**, 800–809.
- 6. Hellenthal, G., Busby, G.B.J., Band, G., Wilson, J.F., Capelli, C., Falush, D. and Myers, S. (2014) A genetic atlas of human admixture history. *Science*, **343**, 747–751.
- 7. Arauna, L.R., Mendoza-Revilla, J., Mas-Sandoval, A., Izaabel, H., Bekada, A., Benhamamouch, S., Fadhlaoui-Zid, K., Zalloua, P., Hellenthal, G. and Comas, D. (2017) Recent Historical Migrations Have Shaped the Gene Pool of Arabs and Berbers in North Africa. *Mol. Biol. Evol.*, **34**, 318–329.
- 8. Banihashemi, K. (2009) Iranian human genome project: Overview of a research process among Iranian ethnicities. *Indian J. Hum. Genet.*, **15**, 88–92.
- 9. Fattahi, Z., Beheshtian, M., Mohseni, M., Poustchi, H., Sellars, E., Nezhadi, S.H., Amini, A., Arzhangi, S., Jalalvand, K., Jamali, P., *et al.* (2019) Iranome: A catalog of genomic variations in the Iranian population. *Hum. Mutat.*, **40**, 1968–1984.
- 10. Fakhro, K.A., Staudt, M.R., Ramstetter, M.D., Robay, A., Malek, J.A., Badii, R., Al-Marri, A.A.-N., Khalil, C.A., Al-Shakaki, A., Chidiac, O., *et al.* (2016) The Qatar genome: a population-specific tool for precision medicine in the Middle East. *Human Genome Variation*, **3**, 1–7.
- 11. Mbarek, H., Gandhi, G.D., Selvaraj, S., Al-Muftah, W., Badji, R., Al-Sarraj, Y., Saad, C., Darwish, D., Alvi, M., Fadl, T., et al. (2021) Qatar Genome: Insights on Genomics from the Middle East. *medRxiv*, 2021.09.19.21263548.
- 12. Razali, R.M., Rodriguez-Flores, J., Ghorbani, M., Naeem, H., Aamer, W., Aliyev, E., Jubran, A., Clark, A.G., Fakhro, K.A. and Mokrab, Y. (2021) Thousands of Qatari genomes inform human migration history and improve imputation of Arab haplotypes. *Nat. Commun.*, **12**, 1–16.
- 13. Bashwari, L.A., Al-Mulhim, A.A., Ahmad, M.S. and Ahmed, M.A. (2001) Frequency of ABO blood groups in the Eastern region of Saudi Arabia. *Saudi Med. J.*, **22**, 1008–1012.
- 14. Owaidah, A.Y., Naffaa, N.M., Alumran, A. and Alzahrani, F. (2020) Phenotype Frequencies of Major Blood Group Systems (Rh, Kell, Kidd, Duffy, MNS, P, Lewis, and Lutheran) Among Blood Donors in the Eastern Region of Saudi Arabia. *J. Blood Med.*, **11**, 59–65.
- 15. Sarhan, M.A., Saleh, K.A. and Bin-Dajem, S.M. (2009) Distribution of ABO blood groups and rhesus factor in Southwest Saudi Arabia. *Saudi Med. J.*, **30**, 116–119.
- 16. Ameen, R., Al Shemmari, S., Harris, S., Teramura, G. and Delaney, M. (2020) Classification of major and minor blood group antigens in the Kuwaiti Arab population. *Transfus. Apher. Sci.*, **59**, 102748.
- 17. Yip, S.P., Choi, P.S., Lee, S.Y., Leung, K.H., El-Zawahri, M.M. and Luqmani, Y.A. (2006) ABO blood group in Kuwaitis: detailed allele frequency distribution and identification of novel

- alleles. Transfusion . 46. 773-779.
- 18. Natarajan, J. and Joseph, M.A. (2021) Premarital screening for genetic blood disorders an integrated review on the knowledge and attitudes of Middle Eastern university students. Premarital screening for genetic blood disorders an integrated review on the knowledge and attitudes of Middle Eastern university students. *Middle East Fertility Society Journal* (2021), 26.
- 19. Alsaeed, E.S., Farhat, G.N., Assiri, A.M., Memish, Z., Ahmed, E.M., Saeedi, M.Y., Al-Dossary, M.F. and Bashawri, H. (2017) Distribution of hemoglobinopathy disorders in Saudi Arabia based on data from the premarital screening and genetic counseling program, 2011–2015. Distribution of hemoglobinopathy disorders in Saudi Arabia based on data from the premarital screening and genetic counseling program, 2011–2015. *Journal of Epidemiology and Global Health* (2017), 7, S41.
- 20. Bailey, M., Gibbs, M., Dani, N., Mendell, A. and Thompson, M. (2019) Burden of Illness of Sickle Cell Disease in Countries of the Middle East: A Systematic Literature Review. Burden of Illness of Sickle Cell Disease in Countries of the Middle East: A Systematic Literature Review. *Blood* (2019), 134, 5867–5867.
- 21. Scott, E.M., Halees, A., Itan, Y., Spencer, E.G., He, Y., Azab, M.A., Gabriel, S.B., Belkadi, A., Boisson, B., Abel, L., *et al.* (2016) Characterization of Greater Middle Eastern genetic variation for enhanced disease gene discovery. *Nat. Genet.*, **48**, 1071–1076.
- 22. MacArthur, J.A.L., Morales, J., Tully, R.E., Astashyn, A., Gil, L., Bruford, E.A., Larsson, P., Flicek, P., Dalgleish, R., Maglott, D.R., *et al.* (2014) Locus Reference Genomic: reference sequences for the reporting of clinically relevant sequence variants. *Nucleic Acids Res.*, **42**. D873–8.
- 23. Rophina, M., Teh, L.K., Sivasubbu, S., Scaria, V. and Salleh, M.Z. (2021) Genomic map of blood group alleles in Malaysian indigenous Orang Asli population from whole genome sequences. *medRxiv*, 2021.12.04.21267232.
- 24. Storry, J.R., Clausen, F.B., Castilho, L., Chen, Q., Daniels, G., Denomme, G., Flegel, W.A., Gassner, C., de Haas, M., Hyland, C., et al. (2019) International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology: Report of the Dubai, Copenhagen and Toronto meetings. Vox Sang., 114, 95–102.
- 25. Patnaik, S.K., Helmberg, W. and Blumenfeld, O.O. (2014) BGMUT Database of Allelic Variants of Genes Encoding Human Blood Group Antigens. *Transfus. Med. Hemother.*, **41**, 346–351.
- 26. Möller, M., Jöud, M., Storry, J.R. and Olsson, M.L. (2016) Erythrogene: a database for in-depth analysis of the extensive variation in 36 blood group systems in the 1000 Genomes Project. *Blood Adv*, **1**, 240–249.
- 27. Wagner, F.F. and Flegel, W.A. (2014) The Rhesus Site. *Transfus. Med. Hemother.*, **41**, 357–363.
- 28. Lane, W.J., Vege, S., Mah, H.H., Lomas-Francis, C., Aguad, M., Smeland-Wagman, R., Koch, C., Killian, J.M., Gardner, C.L., De Castro, M., *et al.* (2019) Automated typing of red blood cell and platelet antigens from whole exome sequences. *Transfusion*, **59**, 3253–3263.
- 29. Lane, W.J., Westhoff, C.M., Gleadall, N.S., Aguad, M., Smeland-Wagman, R., Vege, S., Simmons, D.P., Mah, H.H., Lebo, M.S., Walter, K., *et al.* (2018) Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. *Lancet Haematol*, **5**, e241–e251.
- 30. Rophina, M., Pandhare, K., Jadhao, S., Nagaraj, S.H. and Scaria, V. (2021) BGvar: A comprehensive resource for blood group immunogenetics. *Transfus. Med.*
- 31. Ng, P.C. and Henikoff, S. (2003) SIFT: Predicting amino acid changes that affect protein

- function. Nucleic Acids Res., 31, 3812-3814.
- 32. Adzhubei, I., Jordan, D.M. and Sunyaev, S.R. (2013) Predicting functional effect of human missense mutations using PolyPhen-2. *Curr. Protoc. Hum. Genet.*, **Chapter 7**, Unit7.20.
- 33. Gnad, F., Baucom, A., Mukhyala, K., Manning, G. and Zhang, Z. (2013) Assessment of computational methods for predicting the effects of missense mutations in human cancers. *BMC Genomics*, **14 Suppl 3**, S7.
- 34. Shihab, H.A., Gough, J., Cooper, D.N., Stenson, P.D., Barker, G.L.A., Edwards, K.J., Day, I.N.M. and Gaunt, T.R. (2013) Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. *Hum. Mutat.*, **34**, 57–65.
- 35. Choi, Y. and Chan, A.P. (2015) PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. *Bioinformatics*, **31**, 2745–2747.
- 36. Rentzsch, P., Witten, D., Cooper, G.M., Shendure, J. and Kircher, M. (2019) CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.*, **47**, D886–D894.
- 37. Davydov, E.V., Goode, D.L., Sirota, M., Cooper, G.M., Sidow, A. and Batzoglou, S. (2010) Identifying a high fraction of the human genome to be under selective constraint using GERP++. *PLoS Comput. Biol.*, **6**, e1001025.
- 38. Pollard, K.S., Hubisz, M.J., Rosenbloom, K.R. and Siepel, A. (2010) Detection of nonneutral substitution rates on mammalian phylogenies. *Genome Res.*, **20**, 110–121.
- 39. Wang, K., Li, M. and Hakonarson, H. (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.*, **38**, e164.
- 40. Danecek, P., Auton, A., Abecasis, G., Albers, C.A., Banks, E., DePristo, M.A., Handsaker, R.E., Lunter, G., Marth, G.T., Sherry, S.T., *et al.* (2011) The variant call format and VCFtools. *Bioinformatics*, **27**, 2156–2158.
- 41. Lane, W.J., Westhoff, C.M., Uy, J.M., Aguad, M., Smeland-Wagman, R., Kaufman, R.M., Rehm, H.L., Green, R.C., Silberstein, L.E. and MedSeq Project (2016) Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle. *Transfusion*, **56**, 743–754.
- 42. Yin, Q., Srivastava, K., Brust, D.G. and Flegel, W.A. (2021) Transfusion support during childbirth for a woman with anti-U and the allele. *Immunohematology*, **37**, 1–4.
- 43. Lawler, S.D. and Van Loghem, J.J., Jr (1947) The rhesus antigen CW causing haemolytic disease of the newborn. *Lancet*, **2**, 545.
- 44. Wester, E.S., Storry, J.R. and Olsson, M.L. (2011) Characterization of Jk(a+(weak)): a new blood group phenotype associated with an altered JK*01 allele. *Transfusion*, **51**, 380–392.
- 45. Wu, P.C., Chyan, T.-W., Feng, S.-H., Chen, M.-H. and Pai, S.-C. (2019) Genotyping and serotyping profiles showed weak Jk presentation for previously typed as Jk donors. *Vox Sang.*, **114**, 268–274.
- 46. Huang H.J. and Tagawa H. (1982) [Hemolytic disease of the newborn due to anti-Ku (author's transl)]. *Nihon Sanka Fujinka Gakkai Zasshi*, **34**, 119–121.
- 47. Lee, S., Wu, X., Reid, M., Zelinski, T. and Redman, C. (1995) Molecular basis of the Kell (K1) phenotype. Molecular basis of the Kell (K1) phenotype. *Blood* (1995), 85, 912–916.
- 48. Daniels, G., Hadley, A. and Green, C.A. (2003) Causes of fetal anemia in hemolytic disease due to anti-K. *Transfusion*, **43**, 115–116.
- 49. Felimban, R.I. and Sumeda, S.M. (2021) Distribution of Kell antigens K, k, Kp, and Kp among blood donors in Jeddah city of Western Saudi Arabia. *Asian J. Transfus. Sci.*, **15**, 75–81.

- 50. Alalshaikh, M., Almalki, Y., Hasanato, R., Almomen, A., Alsughayir, A., Alabdullateef, A., Sabbar, A. and Alsuhaibani, O. (2021) Frequency of Rh and K antigens in blood donors in Riyadh. Frequency of Rh and K antigens in blood donors in Riyadh. *Hematology, Transfusion and Cell Therapy* (2021).
- 51. Vendrame, T.A.P., Silva, F.S.A., Aravechia, M.G., Santos, L.D., Costa, T.H., Sirianni, M.F.M., Pedro, T., Cortez, A.J.P., Castilho, L., Latini, F., et al. (2021) ANTI-CRA: A FAMILY STUDY OF A BRAZILIAN FAMILY IN MOLECULAR TIMES. ANTI-CRA: A FAMILY STUDY OF A BRAZILIAN FAMILY IN MOLECULAR TIMES. Hematology, Transfusion and Cell Therapy (2021), 43, S314–S315.
- 52. Kwon, M.Y., Su, L., Arndt, P.A., Garratty, G. and Blackall, D.P. (2004) Clinical significance of anti-Jra: report of two cases and review of the literature. *Transfusion*, **44**, 197–201.
- 53. Peyrard, T., Pham, B.-N., Arnaud, L., Fleutiaux, S., Brossard, Y., Guerin, B., Desmoulins, I., Rouger, P. and Le Pennec, P.-Y. (2008) Fatal hemolytic disease of the fetus and newborn associated with anti-Jra. Fatal hemolytic disease of the fetus and newborn associated with anti-Jra. *Transfusion* (2008), 48, 1906–1911.
- 54. Levene, C., Sela, R., Dvilansky, A., Yermiahu, T. and Daniels, G. (1986) The Jr(a-) phenotype and anti-Jra in two Beduin Arab women in Israel. The Jr(a-) phenotype and anti-Jra in two Beduin Arab women in Israel. *Transfusion* (1986), 26, 119–120.
- 55. Liu, S., Ajne, G., Wikman, A., Lindqvist, C., Reilly, M. and Tiblad, E. (2021) Management and clinical consequences of red blood cell antibodies in pregnancy: A population-based cohort study. *Acta Obstet. Gynecol. Scand.*, **100**, 2216–2225.
- 56. Sheeladevi, C.S., Suchitha, S., Manjunath, G.V. and Murthy, S. (2013) Hemolytic Disease of the Newborn Due to Anti-c Isoimmunization: A Case Report. *Indian J. Hematol. Blood Transfus.*, **29**, 155–157.
- 57. Shastry, S. and Bhat, S. (2014) Severe hemolytic disease of newborn in a rh d-positive mother: time to mandate the antenatal antibody screening. *J. Obstet. Gynaecol. India*, **64**, 291–292.
- 58. Flesch, B.K., Scherer, V., Just, B., Opitz, A., Ochmann, O., Janson, A., Steitz, M. and Zeiler, T. (2020) Molecular Blood Group Screening in Donors from Arabian Countries and Iran Using High-Throughput MALDI-TOF Mass Spectrometry and PCR-SSP. *Transfus. Med. Hemother.*, **47**, 396–408.
- 59. [No title] https://www.jrmds.in/articles/abo-and-rhesus-blood-groups-distribution-in-healthy-indi viduals-an-update-cross-sectional-study-from-tertiary-care-cente.pdf (accessed Mar 21, 2022).
- 60. Elsayid, M., Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences and Riyadh (2017) Phenotypic Profile of Kell Blood Group System among Saudi Donors at King Abdulaziz Medical City-Riyadh. Phenotypic Profile of Kell Blood Group System among Saudi Donors at King Abdulaziz Medical City-Riyadh. *Journal of Medical Science And clinical Research* (2017), 05, 15654–15657.
- 61. Sajwani, F.H., Amer, A.M., Khamis, F.M. and AlShamsi, S.R. (2021) Prevalence of major blood group antigens in blood donors at a main donation center in United Arab Emirates. Prevalence of major blood group antigens in blood donors at a main donation center in United Arab Emirates. *Immunohematology* (2021), 37, 171–177.
- 62. Lee, S., Wu, X., Reid, M. and Redman, C. (2003) Molecular basis of the K:6,-7 [Js(a b-)] phenotype in the Kell blood group system. Molecular basis of the K:6,-7 [Js(a b-)] phenotype in the Kell blood group system. *Transfusion* (2003), 35, 822–825.

- 63. Williams, T.N. and Weatherall, D.J. (2012) World distribution, population genetics, and health burden of the hemoglobinopathies. *Cold Spring Harb. Perspect. Med.*, **2**, a011692.
- 64. Al-Jawaldeh, A., Taktouk, M., Doggui, R., Abdollahi, Z., Achakzai, B., Aguenaou, H., Al-Halaika, M., Almamary, S., Barham, R., Coulibaly-Zerbo, F., *et al.* (2021) Are Countries of the Eastern Mediterranean Region on Track towards Meeting the World Health Assembly Target for Anemia? A Review of Evidence. *Int. J. Environ. Res. Public Health*, **18**.
- 65. El-Hazmi, M.A.F., Al-Hazmi, A.M. and Warsy, A.S. (2011) Sickle cell disease in Middle East Arab countries. *Indian J. Med. Res.*, **134**, 597–610.
- 66. Hindawi, S. (2020) Evolution of Blood Transfusion Medicine in Saudi Arabia. *Transfusion*, **60 Suppl 1**, S2–S3.